Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer

BACKGROUND: The association between the development of checkpoint inhibitor pneumonitis (CIP) with tumor response and survival has remained unclear so far. The aim of the present study was to evaluate the association between CIP and the clinical efficacy of anti‐programmed cell death‐1 antibody in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Kana, Ono, Hirotaka, Toi, Yukihiro, Sugisaka, Jun, Aso, Mari, Saito, Ryohei, Kawana, Sachiko, Aiba, Tomoiki, Odaka, Tetsuo, Matsuda, Suguru, Saito, Shin, Narumi, Akane, Ogasawara, Takahiro, Shimizu, Hisashi, Domeki, Yutaka, Terayama, Keisuke, Kawashima, Yosuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro, Sugawara, Shunichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290230/
https://www.ncbi.nlm.nih.gov/pubmed/34121358
http://dx.doi.org/10.1002/cam4.4045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290230/
https://www.ncbi.nlm.nih.gov/pubmed/34121358
http://dx.doi.org/10.1002/cam4.4045

Ejemplares similares